Key Points
- CFO Renee Gaeta sold 4,498 shares at an average $3.67, totaling about $16,508. The sale covered tax withholding on vested equity awards; she retained 176,342 shares.
- Outset Medical’s latest quarterly results modestly beat expectations: adjusted loss was $0.68 per share versus a $0.69 estimate, while revenue of $33.6 million exceeded the $31.4 million forecast.
- The stock was reported down 6.8% and opened at $3.16 on Wednesday. Analysts’ consensus rating was Hold, with an average price target of $10.
Outset Medical, Inc. (NASDAQ:OM - Get Free Report) CEO Leslie Trigg sold 3,403 shares of the firm's stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $3.67, for a total value of $12,489.01. Following the transaction, the chief executive officer owned 191,194 shares of the company's stock, valued at $701,681.98. This trade represents a 1.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Outset Medical Price Performance
Shares of OM stock opened at $3.16 on Wednesday. The stock's fifty day simple moving average is $3.75 and its 200 day simple moving average is $4.09. Outset Medical, Inc. has a one year low of $2.84 and a one year high of $6.49. The firm has a market cap of $59.63 million, a price-to-earnings ratio of -0.82 and a beta of 1.93. The company has a debt-to-equity ratio of 1.19, a current ratio of 4.86 and a quick ratio of 3.85.
Outset Medical (NASDAQ:OM - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.01. The firm had revenue of $33.60 million during the quarter, compared to analyst estimates of $31.40 million. Outset Medical had a negative return on equity of 66.98% and a negative net margin of 58.33%. On average, analysts expect that Outset Medical, Inc. will post -3.51 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp lifted its holdings in shares of Outset Medical by 4.1% in the first quarter. Bank of New York Mellon Corp now owns 62,360 shares of the company's stock valued at $239,000 after purchasing an additional 2,435 shares in the last quarter. Sei Investments Co. grew its holdings in shares of Outset Medical by 15.5% during the first quarter. Sei Investments Co. now owns 35,366 shares of the company's stock worth $136,000 after buying an additional 4,738 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Outset Medical during the second quarter worth about $98,000. Empowered Funds LLC bought a new position in shares of Outset Medical during the third quarter worth about $74,000. Finally, Marquette Asset Management LLC acquired a new stake in Outset Medical in the 2nd quarter valued at approximately $212,000.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on OM. Wall Street Zen raised shares of Outset Medical from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Weiss Ratings downgraded shares of Outset Medical from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, August 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Outset Medical has an average rating of "Hold" and a consensus target price of $10.00.
Get Our Latest Stock Report on OM
About Outset Medical
(
Get Free Report)
Outset Medical is a medical technology company that develops and sells products for hemodialysis, a treatment that filters waste and excess fluid from the blood. Its main product is the Tablo Hemodialysis System, an integrated dialysis platform designed for use in hospitals, clinics and home settings. Tablo combines dialysis equipment with water purification and a touchscreen interface, aiming to simplify treatment setup and operation. The system also supports access to treatment data through connected software tools.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].